Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2025-09-23 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-09-23 English
CMS Grants Transitional Pass-Through Status for Gozellix 3 pages 215.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 23 September 2025. It announces that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through payment status for their product Gozellix. The content focuses on regulatory and reimbursement status updates, commercial strategy implications, and product information. There are no financial statements, detailed financial performance data, or management discussion of financial results. The document is a formal announcement of a regulatory and commercial milestone rather than a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the CMS decision and its impact. Therefore, the document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2025-09-22 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-09-09 English
Telix and FDA Agree Resubmission Pathway for Pixclara NDA 3 pages 214.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding an agreement with the FDA on the resubmission pathway for a New Drug Application (NDA) for TLX101-CDx. It discusses regulatory interactions, plans for resubmission, and forward-looking statements about the drug approval process. There are no financial statements, detailed financial data, or comprehensive report content. The document is a regulatory update announcement about a specific event related to the company's drug approval process. It is not an annual report, earnings release, or any detailed financial or management report. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other more specific categories.
2025-09-08 English
Pending Release of Shares from Voluntary Escrow 2 pages 208.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the pending release of shares from voluntary escrow. It references compliance with ASX Listing Rule 3.10A and details the number of shares and escrow release date. The content is focused on a specific capital event related to share release, not a financial report or earnings release. There are no financial statements or detailed financial data presented. The document is an announcement about a capital structure event (release of shares from escrow), which fits best under Capital/Financing Update (CAP). The document length is 6846 characters, which is sufficient for a detailed announcement but does not contain financial reports or management discussion. Therefore, the classification is CAP with high confidence.
2025-09-04 English
Application for quotation of securities - TLX 8 pages 25.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue dates, prices, and related information. There is no financial performance data, earnings information, or management discussion. The document is focused on the capital market activity of issuing and quoting new shares. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other categories. Therefore, the appropriate classification is SHA (Share Issue/Capital Change). The document length and detail support a high confidence in this classification.
2025-09-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.